Roche Holding stock trades at EUR 386.05 with a 23.5 P/ E

Published on 10/09/2026 at 16:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche Holding stock costs EUR 386.05 on October 9, 2026, up 1.36 percent versus EUR 380.88. Sales are due October 22, 2026.

Key points in brief

Roche Holding traded at EUR 386.05 at Lang & Schwarz on October 9, 2026, up 1.36 percent versus EUR 380.88.
The quote showed a EUR 385.95 bid and EUR 386.15 ask, while the finance snapshot listed a 23.5 P/E.
Roche will publish third-quarter 2026 sales on October 22, 2026, before the Swiss Stock Exchange opens.
Roche's USD market capitalization was USD 293.3 billion, compared with USD 273.5 billion for Novartis and USD 247.8 billion for AstraZeneca.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

At 4:07 p.m. CEST on October 9, 2026, Roche Holding (CH1499059983) was trading at EUR 386.05 at Lang & Schwarz, up 1.36 percent versus the prior close of EUR 380.88. The quote gives German-market investors a clear intraday reference ahead of Roche's next scheduled sales update.

Quote holds above prior close

The Lang & Schwarz bid was EUR 385.95 and the ask was EUR 386.15 on October 9, 2026. That EUR 0.20 spread places the latest quote between tightly grouped buy and sell indications, while the daily move remains positive at 1.36 percent.

Roche's market capitalization was USD 293.3 billion as of October 9, 2026. The same quote snapshot listed a P/E ratio of 23.5 and a dividend yield of 3.0 percent, giving the price report two valuation reference points without converting the company's USD market data into euros.

Next sales date is October 22

Roche said in an investor update dated September 22, 2026, that it will publish third-quarter 2026 sales before the Swiss Stock Exchange opens on October 22, 2026. The presentation is scheduled for 2:00 p.m. CEST, so the date is the next fixed company event in the market calendar.

The upcoming release matters because it will provide the next reported sales checkpoint after the first half of 2026. The company investor page identifies 2025 core earnings per share growth of 11 percent and 39 million patients treated with Roche medicines in fiscal year 2025, historical operating markers that remain separate from the October market snapshot.

Comparison with peers

Roche Holding: plus 1.36 percent, P/E 23.5, market capitalization USD 293.3 billion
Novartis (NYSE, USD): plus 0.56 percent, P/E 22.0, market capitalization USD 273.5 billion
AstraZeneca (Nasdaq, USD): plus 0.64 percent, P/E 23.9, market capitalization USD 247.8 billion

Analyst target stays in CHF

Investing.com listed HSBC at Hold with a CHF 380.00 target and a Maintain action dated October 9, 2026. The target is in Swiss francs, while the reference quote in this report is in euros, so the two figures are separate market indicators.

Roche Holding stock at EUR 386.05

Roche Holding was trading at EUR 386.05 at Lang & Schwarz on October 9, 2026 at 4:07 p.m. CEST, plus 1.36 percent versus the Lang & Schwarz prior close of EUR 380.88 on October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.